WallStSmart

Butterfly Network Inc (BFLY)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 50454% more annual revenue ($56.69B vs $112.14M). NVS leads profitability with a 22.5% profit margin vs -66.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).

BFLY

Avoid

27

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -2.75

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BFLY.

NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BFLY2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
39.5%10/10

Revenue surging 39.5% year-over-year

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

BFLY4 concerns · Avg: 3.5/10
Price/BookValuation
10.2x4/10

Trading at 10.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.95B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BFLY

The strongest argument for BFLY centers on Revenue Growth, Debt/Equity. Revenue growth of 39.5% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : BFLY

The primary concerns for BFLY are Price/Book, EPS Growth, Market Cap.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

BFLY profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.

BFLY carries more volatility with a beta of 2.09 — expect wider price swings.

BFLY is growing revenue faster at 39.5% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 27/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Butterfly Network Inc

HEALTHCARE · MEDICAL DEVICES · USA

Butterfly Network, Inc., a digital health company, develops, manufactures, and markets ultrasound imaging solutions in the United States and internationally. The company is headquartered in Guilford, Connecticut.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?